Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 8/2010

01-08-2010 | Original Paper

Epigenetic silencing of WIF-1 in hepatocellular carcinomas

Authors: Yun Deng, Bin Yu, Qin Cheng, Jie Jin, Haiyan You, Ronghu Ke, Ning Tang, Qiujin Shen, Huiqun Shu, Genfu Yao, Zhigang Zhang, Wenxin Qin

Published in: Journal of Cancer Research and Clinical Oncology | Issue 8/2010

Login to get access

Abstract

Purpose

To examine the expression profile and promoter methylation status of WIF-1 in hepatocellular carcinoma (HCC) and identify the possible relationship between the WIF-1 expression pattern and promoter methylation status.

Methods

Quantitative real-time PCR was performed to detect mRNA level of WIF-1 in 4 HCC cell lines, 15 paired HCC clinical samples and 3 normal liver tissues. Methylation-specific PCR and bisulfite DNA sequencing were used in methylation analysis. In vitro assays for HCC cells, colony formation and cell proliferation assay were carried out to observe the effect of WIF-1 on cell growth; TOP-flash luciferase analysis was employed to determine its role in the Wnt pathway.

Results

Quantitative real-time PCR analysis showed the extensive low expression of WIF-1 mRNA in HCC, and this down-regulation was generally dependent on the degree of methylation at its promoter region. In vitro assays indicated WIF-1 can inhibit cell growth by blocking Wnt signaling in HCC cells.

Conclusions

WIF-1 silencing as a result of its promoter hypermethylation may be a frequent event in HCC.
Literature
go back to reference Batra S, Shi Y, Kuchenbecker KM et al (2006) Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem Biophys Res Commun 342:1228–1232CrossRefPubMed Batra S, Shi Y, Kuchenbecker KM et al (2006) Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem Biophys Res Commun 342:1228–1232CrossRefPubMed
go back to reference Bengochea A, de Souza MM, Lefrançois L et al (2008) Common dysregulation of Wnt/frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer 99:143–150CrossRefPubMed Bengochea A, de Souza MM, Lefrançois L et al (2008) Common dysregulation of Wnt/frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer 99:143–150CrossRefPubMed
go back to reference Cebrat M, Strzadala L, Kisielow P (2004) Wnt inhibitory factor-1: a candidate for a new player in tumorigenesis of intestinal epithelial cells. Cancer Lett 206:107–113CrossRefPubMed Cebrat M, Strzadala L, Kisielow P (2004) Wnt inhibitory factor-1: a candidate for a new player in tumorigenesis of intestinal epithelial cells. Cancer Lett 206:107–113CrossRefPubMed
go back to reference Civenni G, Holbro T, Hynes NE (2003) Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells. EMBO Rep 4:166–171CrossRefPubMed Civenni G, Holbro T, Hynes NE (2003) Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells. EMBO Rep 4:166–171CrossRefPubMed
go back to reference Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674–687CrossRefPubMed Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674–687CrossRefPubMed
go back to reference He B, Reguart N, You L et al (2005a) Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 24:3054–3058CrossRefPubMed He B, Reguart N, You L et al (2005a) Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 24:3054–3058CrossRefPubMed
go back to reference He B, Lee AY, Dadfarmay S et al (2005b) Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. Cancer Res 65:743–748PubMed He B, Lee AY, Dadfarmay S et al (2005b) Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. Cancer Res 65:743–748PubMed
go back to reference Hsieh JC, Kodjabachian L, Rebbert ML et al (1999) A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 398:431–436CrossRefPubMed Hsieh JC, Kodjabachian L, Rebbert ML et al (1999) A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 398:431–436CrossRefPubMed
go back to reference Huang H, He X (2008) Wnt/β-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol 20:119–125CrossRefPubMed Huang H, He X (2008) Wnt/β-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol 20:119–125CrossRefPubMed
go back to reference Kensler TW, Qian GS, Chen JG et al (2003) Translational strategies for cancer prevention in liver. Nat Rev Cancer 3:321–329CrossRefPubMed Kensler TW, Qian GS, Chen JG et al (2003) Translational strategies for cancer prevention in liver. Nat Rev Cancer 3:321–329CrossRefPubMed
go back to reference Kim M, Lee HC, Tsedensodnom O et al (2008) Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/β-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol 48:780–791CrossRefPubMed Kim M, Lee HC, Tsedensodnom O et al (2008) Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/β-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol 48:780–791CrossRefPubMed
go back to reference Kirikoshi H, Sekihara H, Katoh M (2001) Expression of WNT14 and WNT14B mRNAs in human cancer, up-regulation of WNT14 by IFN gamma and up-regulation of WNT14B by β-estradiol. Int J Oncol 19:1221–1225PubMed Kirikoshi H, Sekihara H, Katoh M (2001) Expression of WNT14 and WNT14B mRNAs in human cancer, up-regulation of WNT14 by IFN gamma and up-regulation of WNT14B by β-estradiol. Int J Oncol 19:1221–1225PubMed
go back to reference Klaus A, Birchmeier W (2008) Wnt signalling and its impact on development and cancer. Nat Rev Cancer 8:387–398CrossRefPubMed Klaus A, Birchmeier W (2008) Wnt signalling and its impact on development and cancer. Nat Rev Cancer 8:387–398CrossRefPubMed
go back to reference Lee HC, Kim M, Wands JR (2006) Wnt/frizzled signaling in hepatocellular carcinoma. Front Biosci 11:1901–1915CrossRefPubMed Lee HC, Kim M, Wands JR (2006) Wnt/frizzled signaling in hepatocellular carcinoma. Front Biosci 11:1901–1915CrossRefPubMed
go back to reference Lin YC, You L, Xu Z et al (2007) Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth. Hum Gene Ther 18:379–386CrossRefPubMed Lin YC, You L, Xu Z et al (2007) Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth. Hum Gene Ther 18:379–386CrossRefPubMed
go back to reference Mazieres J, He B, You L et al (2004) Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 64:4717–4720CrossRefPubMed Mazieres J, He B, You L et al (2004) Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 64:4717–4720CrossRefPubMed
go back to reference Saitoh T, Mine T, Katoh M (2002) Frequent up-regulation of WNT5A mRNA in primary gastric cancer. Int J Mol Med 9:515–519PubMed Saitoh T, Mine T, Katoh M (2002) Frequent up-regulation of WNT5A mRNA in primary gastric cancer. Int J Mol Med 9:515–519PubMed
go back to reference Smith K, Bui TD, Poulsom R et al (1999) Up-regulation of macrophage wnt gene expression in adenoma-carcinoma progression of human colorectal cancer. Br J Cancer 81:496–502CrossRefPubMed Smith K, Bui TD, Poulsom R et al (1999) Up-regulation of macrophage wnt gene expression in adenoma-carcinoma progression of human colorectal cancer. Br J Cancer 81:496–502CrossRefPubMed
go back to reference Staal FJ, Luis TC, Tiemessen MM (2008) WNT signalling in the immune system: WNT is spreading its wings. Nat Rev Immunol 8:581–593CrossRefPubMed Staal FJ, Luis TC, Tiemessen MM (2008) WNT signalling in the immune system: WNT is spreading its wings. Nat Rev Immunol 8:581–593CrossRefPubMed
go back to reference Urakami S, Shiina H, Enokida H et al (2006) Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/β-catenin signaling pathway. Clin Cancer Res 12:383–391CrossRefPubMed Urakami S, Shiina H, Enokida H et al (2006) Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/β-catenin signaling pathway. Clin Cancer Res 12:383–391CrossRefPubMed
go back to reference Wissmann C, Wild PJ, Kaiser S et al (2003) WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 201:204–212CrossRefPubMed Wissmann C, Wild PJ, Kaiser S et al (2003) WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 201:204–212CrossRefPubMed
go back to reference Xie L, Qin WX, Li JJ et al (2007) BNIPL-2 promotes the invasion and metastasis of human hepatocellular carcinoma cells. Oncol Rep 17:605–610PubMed Xie L, Qin WX, Li JJ et al (2007) BNIPL-2 promotes the invasion and metastasis of human hepatocellular carcinoma cells. Oncol Rep 17:605–610PubMed
Metadata
Title
Epigenetic silencing of WIF-1 in hepatocellular carcinomas
Authors
Yun Deng
Bin Yu
Qin Cheng
Jie Jin
Haiyan You
Ronghu Ke
Ning Tang
Qiujin Shen
Huiqun Shu
Genfu Yao
Zhigang Zhang
Wenxin Qin
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 8/2010
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-010-0763-5

Other articles of this Issue 8/2010

Journal of Cancer Research and Clinical Oncology 8/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.